Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody

Donald E Tsai; Ivan Maillard; Stephen J Schuster; Sunita D Nasta; David L Porter; Thomas R Klumpp; David M Goldenberg; Selina M Luger; Abass Alavi; Robert M Sharkey; Kenneth B Hartzell; Edward A Stadtmauer

doi:10.3816/clm.2003.n.015

Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody

Clin Lymphoma. 2003 Jun;4(1):56-9. doi: 10.3816/clm.2003.n.015.

Authors

Donald E Tsai¹, Ivan Maillard, Stephen J Schuster, Sunita D Nasta, David L Porter, Thomas R Klumpp, David M Goldenberg, Selina M Luger, Abass Alavi, Robert M Sharkey, Kenneth B Hartzell, Edward A Stadtmauer

Affiliation

¹ Bone Marrow and Stem Cell Transplant Program, University of Pennsylvania Cancer Center, Philadelphia, 19104, USA. [email protected]

PMID: 12837157
DOI: 10.3816/clm.2003.n.015

Abstract

Ibritumomab tiuxetan is a novel radioimmunotherapeutic agent that has a high response rate in relapsed or chemotherapy-refractory CD20+ B-cell non-Hodgkin's lymphoma. Whereas chemotherapy agents can successfully be used multiple times in a given patient, there are few data on the repeated use of radioimmunotherapy in terms of efficacy or morbidity, and no reports as yet involving radioconjugates that target different antigens We report on a patient who was treated successfully with yttrium-90-labeled humanized anti-CD22 monoclonal antibody (90Y-epratuzumab). Upon relapse 3 years later, the patient was treated again with radioimmunotherapy consisting of 90Y-ibritumomab tiuxetan anti-CD20 monoclonal antibody, with a good response and acceptable bone marrow suppression. This case report demonstrates the potential for repeated treatments with radioimmunotherapy agents in patients with chemotherapy-refractory non-Hodgkin's lymphoma.

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Antigens, CD / immunology*
Antigens, CD20 / immunology*
Antigens, Differentiation, B-Lymphocyte / immunology*
B-Lymphocytes / immunology
B-Lymphocytes / pathology
Cell Adhesion Molecules*
Disease Progression
Humans
Lectins / immunology*
Lymphoma, Non-Hodgkin / immunology
Lymphoma, Non-Hodgkin / radiotherapy*
Male
Middle Aged
Neoplasm Recurrence, Local / immunology
Neoplasm Recurrence, Local / radiotherapy*
Radioimmunotherapy / methods*
Radiopharmaceuticals
Sialic Acid Binding Ig-like Lectin 2
Treatment Outcome
Yttrium Radioisotopes / therapeutic use*

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antigens, CD
Antigens, CD20
Antigens, Differentiation, B-Lymphocyte
CD22 protein, human
Cell Adhesion Molecules
Lectins
Radiopharmaceuticals
Sialic Acid Binding Ig-like Lectin 2
Yttrium Radioisotopes
epratuzumab
ibritumomab tiuxetan